Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma Phase 1 clinical trial will enroll 88 healthy volunteers in the United KingdomETH47 is a first-in-class, broadly protective antiviral candidate developed using Ethris’ proprietary platform...

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received...

Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissueEthris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet...

Ethris Joins Alliance for mRNA Medicines as a Founding Member MUNICH, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today it will be...

DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering Successful vaccine candidate combining DIOSynVax's computational multi-virus vaccine antigen payload technology and Ethris’ proprietary non-immunogenic messenger RNA (SNIM mRNA) and lipidoid...